NSE: SUDEEPPHRM · BSE: 544619 · ISIN INE0QPI01025
Sudeep Pharma Limited stock analysis
Sudeep Pharma Limited ranks #139 in the TickerSutra evidence-ranked universe with a score of 71/100 and 89% data confidence. The latest captured fundamentals show ROCE of 28.2%, quarterly sales growth of 26.7% and quarterly profit growth of 31.6%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 28.2%
- Low debt/equity of 0.17×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
- Operating margin has compressed materially
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹343cr | ₹67cr | ₹50cr | 20.0% |
| 2023 | ₹429cr | ₹90cr | ₹62cr | 21.0% |
| 2024 | ₹459cr | ₹183cr | ₹133cr | 40.0% |
| 2025 | ₹502cr | ₹192cr | ₹139cr | 38.0% |
| 2026 | ₹642cr | ₹223cr | ₹174cr | 35.0% |
| TTM | ₹676cr | ₹233cr | ₹184cr | 34.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Sudeep Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineSudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · 23 Sept 2026This is to inform that the officials of the Company will be attending the Investor Conference organized by Nuvama Emerging India CEO Forum 2026 on 28th September 2026 at 10:00 a.m. in Mumbai.
RoutineSudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · 22 Sept 2026Intimation on Cancellation of scheduled Investor /Analyst Meet
MANAGEMENT COMMENTARY
Signals from filed documents
From a geographic perspective, Europe, North America, and the MENA region meaningfully contributed to growth this quarter. Importantly, these international markets continue to carry a stronger margin profile, supported by an increasing contribution from differentiated and value-added products. This performance was delivered despite continued geopolitical uncertainty and volatile raw material markets.
Profit after tax increased to INR40.6 crores compared to INR31.3 crores in the corresponding quarter last year. PAT margin improved to 25.6% from 25%, reflecting enhanced operating leverage and efficient capital management. The pharma and food nutrition segment continued to be primary revenue contributor for this quarter, accounting for 69% of Q1 FY '27 revenue compared to 66% in Q1 FY '26.
The evolving regulatory framework is encouraging battery manufacturers and OEMs to establish reliable supply chains outside China. Recent regulatory developments in China, including Decree No. 837, are expected to further increase the complexity for Chinese companies seeking to establish manufacturing presence outside China and achieve FEOC compliance, as such structures now require g overnment approval for any dives
The Sudeep Pharma Limited August 05, 2026 Page 4 of 18 investments we have made over the past few years in strengthening our international sales team and deepening customer engagement are now translating into tangible business outcomes. While these investments required patience and upfront capital, we are now seeing significantly higher customer traction, a stronger opportunity pipeline, and an increasing sales acros
Shanil Bhayani: So, I mentioned, I think if you see, we've been last year or so, maybe year and a half, we've been around the 35% EBITDA level. Historically, we before we kind of made the investment in building out the sales team and all, we were maybe tracking around 37% -38% EBITDA, and with the right level of utilization of the new greenfield and sales coming from both these markets, we're comfortably we can kind
Mehta brings with him extensive experience in business strategy, finance, and corporate governance. We are confident that his guidance and insight will further strengthen our leadership team and support the company as we enter the next phase of our growth journey. On behalf of the entire Sudeep Pharma family, I extend a warm welcome to him and look forward to his valuable contribution.
Continued logistics disruptions, elevated freight costs, and a sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter. Despite these headwinds, we remained focused on protecting customer relationships, ensuring continuity of supply, and effectively passing on the price increase, which will largely offset the input cost impact in Q2. Looking at the business
So, there is not much of that price pricing today. Majority of that is to do with volume on the back of phosphates, which we have been able to scale significantly with our largest customer. Shanil Bhayani: The second question regarding the bisglycinate portfolio.
Shanil Bhayani: And the third question regarding the greenfield. So, the greenfield facility is currently undergoing regulatory approvals. We are -- the facility has already been approved to supply into the food and nutrition category, and is currently under also undergoing FDA approval, which we expect in this quarter itself.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…